Search

Your search keyword '"Trocha, H."' showing total 101 results

Search Constraints

Start Over You searched for: Author "Trocha, H." Remove constraint Author: "Trocha, H."
101 results on '"Trocha, H."'

Search Results

1. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

2. Infection-related and -unrelated malignancies, HIV and the aging population

3. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors

4. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

5. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients

6. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

7. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

8. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

9. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

10. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

11. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

12. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

13. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

14. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

15. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study

16. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

17. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change

18. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

19. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies

20. Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

21. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

22. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

23. Dialysis and renal transplantation in HIV-infected patients: a European survey

24. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

25. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

26. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

27. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

28. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

29. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients

30. [Staphylococcus aureus sepsis--still life threatening disease]

33. P0319 HBEAG CLEARANCE RATE AND INTERFERON ALFA DOSE

35. Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection?

36. Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy

37. Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: Eurosida Study

38. Response to Antiretroviral Therapy among Patients Exposed to Three Classes of Antiretrovirals: Results from the Eurosida Study

39. [Effectiveness of antiviral treatment of patients with chronic hepatitis C (a Polish multicenter study)]

41. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

43. [Opportunistic infections in HIV-positive patients hospitalized in the Clinic of Infectious Diseases AMG]

44. Autoimmune reactions in HBV and HCV

47. Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report),Pegylowany interferon alpha-2a z rybawiryna w leczeniu przewlekłego wirusowego zapalenia watroby typu C (raport końcowy z badań)

Catalog

Books, media, physical & digital resources